|
| Home : Merck KGaA, Darmstadt, Germany, Strengthens Immuno-Oncology Portfolio through Expansion of F-star Collaboration including LAG-3/PD-L1 Bispecific Antibody |
|
Jun 05
2017 |
Merck KGaA, Darmstadt, Germany, Strengthens Immuno-Oncology Portfolio through Expansion of F-star Collaboration including LAG-3/PD-L1 Bispecific Antibody |
|
DARMSTADT, Germany, June 4, 2017 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, today announced a new strategic collaboration with biopharmaceutical company... |
|
|
|
| Source:http://www.prnewswire.com/news-releases/merck-kgaa-darmstadt-germany-strengthens-immuno-oncology-portfolio-through-expansion-of-f-star-collaboration-including-lag-3pd-l1-bispecific-antibody-300468333.html |
| |
|
Related News
|
» Nexa Digital Marketing Win 'Best Integrated Campaign' at MENA Search Awards 2017
» 'Significant progress' made in identifying London attackers
|
|
|
